<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Drug Related Products</title>
	<atom:link href="http://www.stockbloghub.com/category/drug-related-products/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(PRGO) Perrigo Analyst Maintains Neutral Share rating</title>
		<link>http://www.stockbloghub.com/2012/02/24/prgo-perrigo-analyst-maintains-neutral-share-rating/92526</link>
		<comments>http://www.stockbloghub.com/2012/02/24/prgo-perrigo-analyst-maintains-neutral-share-rating/92526#comments</comments>
		<pubDate>Fri, 24 Feb 2012 18:21:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=92526</guid>
		<description><![CDATA[We have maintained our Neutral rating on Perrigo Company (PRGO) with a target price of $100.00 following appraisal of second quarter of fiscal 2012 results. Perrigo reported second quarter EPS of $1.20, beating the Zacks Consensus Estimate of $1.16 and the year-earlier earnings of $1.05 per share. A robust top-line performance boosted earnings in the quarter. Strong performance by Rx Pharmaceuticals and new products led to the sales growth. Perrigo is a dominant player in the store brand over the counter (OTC) drug market. We believe that Perrigo’s strong position in the brand OTC pharmaceutical market and growing generics and API businesses will help it deliver solid top- and bottom-line growth in the coming years. In the OTC pharmaceutical market, products are sold due to changes in product status from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/24/prgo-perrigo-analyst-maintains-neutral-share-rating/92526/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/11/28/slxp-salix-pharmaceuticals-bull-of-the-day-2/87621</link>
		<comments>http://www.stockbloghub.com/2011/11/28/slxp-salix-pharmaceuticals-bull-of-the-day-2/87621#comments</comments>
		<pubDate>Mon, 28 Nov 2011 20:44:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87621</guid>
		<description><![CDATA[Salix Pharmaceuticals (SLXP) third quarter results exceeded expectations with higher revenues boosting performance. With the company raising its revenue guidance, we have raised our estimates as well. Salix is well-positioned for growth in the gastrointestinal market. We believe lead product Xifaxan will continue to experience solid, above-market trend growth given its safety profile and lack of systemic absorption. We were pleased to see Xifaxan gain approval for the hepatic encephalopathy indication, as we believe that the main potential for Salix lies in gaining approval for additional indications for Xifaxan. Meanwhile, we are pleased to see the company expanding its pipeline through in-licensing deals and acquisitions. We expect the company to continue pursuing suitable in-licensing opportunities in order to grow revenues. We believe the current price represents an attractive entry point ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/slxp-salix-pharmaceuticals-bull-of-the-day-2/87621/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/11/28/slxp-salix-pharmaceuticals-bull-of-the-day/87587</link>
		<comments>http://www.stockbloghub.com/2011/11/28/slxp-salix-pharmaceuticals-bull-of-the-day/87587#comments</comments>
		<pubDate>Mon, 28 Nov 2011 15:58:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87587</guid>
		<description><![CDATA[Salix Pharmaceuticals (SLXP) third quarter results exceeded expectations with higher revenues boosting performance. With the company raising its revenue guidance, we have raised our estimates as well. Salix is well-positioned for growth in the gastrointestinal market. We believe lead product Xifaxan will continue to experience solid, above-market trend growth given its safety profile and lack of systemic absorption. We were pleased to see Xifaxan gain approval for the hepatic encephalopathy indication, as we believe that the main potential for Salix lies in gaining approval for additional indications for Xifaxan. Meanwhile, we are pleased to see the company expanding its pipeline through in-licensing deals and acquisitions. We expect the company to continue pursuing suitable in-licensing opportunities in order to grow revenues. We believe the current price represents an attractive entry point ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/slxp-salix-pharmaceuticals-bull-of-the-day/87587/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Company &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/11/17/prgo-perrigo-company-bull-of-the-day/87137</link>
		<comments>http://www.stockbloghub.com/2011/11/17/prgo-perrigo-company-bull-of-the-day/87137#comments</comments>
		<pubDate>Thu, 17 Nov 2011 21:19:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87137</guid>
		<description><![CDATA[Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of $0.87. Perrigo upped fiscal 2012 earnings per share outlook from $4.50-$4.65 to $4.65-$4.80 due to a strong pipeline and production efficiency gains. Revenue guidance was also increased. We too increased our revenue and earnings estimates for fiscal 2012. We believe that Perrigo&#8217;s strong position in the brand OTC pharmaceutical market and growing generics and API businesses combined with its strong and impressive pipeline can drive growth in fiscal 2012 and beyond. We have thus upgraded our rating from Neutral to Outperform to reflect the company&#8217;s better growth outlook for fiscal 2012. Over the last five years, Perrigo&#8217;s shares have traded in a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/17/prgo-perrigo-company-bull-of-the-day/87137/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Beats Earnings Forecast &#8211; Sales Miss</title>
		<link>http://www.stockbloghub.com/2011/11/02/prgo-perrigo-beats-earnings-forecast-sales-miss/86198</link>
		<comments>http://www.stockbloghub.com/2011/11/02/prgo-perrigo-beats-earnings-forecast-sales-miss/86198#comments</comments>
		<pubDate>Wed, 02 Nov 2011 21:04:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86198</guid>
		<description><![CDATA[Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of 87 cents per share. Light sales performance was offset by a lower tax rate to drive earnings growth. First quarter revenues increased approximately 13% over the prior year to $725.3 million. Total revenues were, however, below the Zacks Consensus Estimate of $748 million. Strong performances by the Active Pharmaceutical Ingredients (API) and Rx Pharmaceuticals segments were offset by sluggish revenues from the company’s Nutritional and Consumer Healthcare businesses due to competitive pressures. The First Quarter of Fiscal 2012 in Detail The revenue performance in the quarter from four of the company’s businesses is detailed below. Consumer Healthcare (CHC): Perrigo reported CHC revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/prgo-perrigo-beats-earnings-forecast-sales-miss/86198/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Downgraded to Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/10/prgo-perrigo-downgraded-to-neutral/78723</link>
		<comments>http://www.stockbloghub.com/2011/07/10/prgo-perrigo-downgraded-to-neutral/78723#comments</comments>
		<pubDate>Mon, 11 Jul 2011 05:36:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78723</guid>
		<description><![CDATA[We recently moved to a Neutral rating on Perrigo Company (PRGO) from Outperform. Our target price on the stock is $94.00. Perrigo’s broad line of store brand pharmaceutical products has the same active ingredients and comparable quality and efficacy as the national brands. This has helped the company become a dominant player in the store brand over the counter (OTC) drug market. We believe that Perrigo’s strong position in the brand OTC pharmaceutical market, and growing generics and API businesses will help it deliver solid top- and bottom-line growth in the coming years. In the OTC pharmaceutical market, some products are sold due to changes in product status from prescription (Rx) only to non-prescription (OTC). This process is called Rx-to-OTC switch and it requires FDA approval. Management estimates that $10 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/10/prgo-perrigo-downgraded-to-neutral/78723/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Cruises Past Estimates &#8211; Lifts Outlook</title>
		<link>http://www.stockbloghub.com/2011/05/08/prgo-perrigo-cruises-past-estimates-lifts-outlook/73520</link>
		<comments>http://www.stockbloghub.com/2011/05/08/prgo-perrigo-cruises-past-estimates-lifts-outlook/73520#comments</comments>
		<pubDate>Sun, 08 May 2011 15:51:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73520</guid>
		<description><![CDATA[Perrigo Company (PRGO) reported earnings per share of $1.07 for the third quarter of fiscal 2011, easily beating the Zacks Consensus Estimate of 96 cents and the year-earlier earnings of 81 cents per share. Results were driven by a solid top-line performance. Third quarter revenues increased 29% over the prior year to $692 million. Total revenues were also above the Zacks Consensus Estimate of $686 million. The year-over-year revenue growth was boosted by strong performances by the company’s generic prescription and active pharmaceutical ingredient (API) businesses. New products added $44 million to revenues. The Quarter in Detail The revenue performance in the quarter from four of the company’s businesses is detailed below. Consumer Healthcare (CHC): Perrigo reported CHC revenue of $425 million in the third quarter, up 13% over the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/prgo-perrigo-cruises-past-estimates-lifts-outlook/73520/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Resolves Manufacturing Issues with FDA</title>
		<link>http://www.stockbloghub.com/2011/04/13/prgo-perrigo-resolves-manufacturing-issues-with-fda/71384</link>
		<comments>http://www.stockbloghub.com/2011/04/13/prgo-perrigo-resolves-manufacturing-issues-with-fda/71384#comments</comments>
		<pubDate>Wed, 13 Apr 2011 22:00:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71384</guid>
		<description><![CDATA[Perrigo Company (PRGO) recently announced the resolution of manufacturing issues at its Allegan, Michigan facility with the US Food and Drug Administration (FDA) following conclusion of re-inspection of the facility by the agency. The FDA commenced a re-inspection of the facility in early March 2011. The FDA concluded that the Allegan facility now meets the regulatory standards, thus removing a major overhang on Perrigo. Perrigo can now look for approval of any export license or generic drug applications for products manufactured from the facility. Approval of products, due to be manufactured at the Allegan facility, like the generic version of Mucinex was being held up due to the FDA warning letter. Following the resolution of the letter, we believe that approval of such generics will be expedited. In April 2010, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/prgo-perrigo-resolves-manufacturing-issues-with-fda/71384/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Auxilium Pharmaceuticals Reports Narrower Loss</title>
		<link>http://www.stockbloghub.com/2010/11/24/auxl-auxilium-pharmaceuticals-reports-narrower-loss/58650</link>
		<comments>http://www.stockbloghub.com/2010/11/24/auxl-auxilium-pharmaceuticals-reports-narrower-loss/58650#comments</comments>
		<pubDate>Thu, 25 Nov 2010 06:56:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58650</guid>
		<description><![CDATA[Auxilium Pharmaceuticals, Inc. (AUXL) reported a third quarter loss of 27 cents per share, narrower than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago loss of 35 cents. Higher revenues helped the company post a lower loss. Net revenues increased 27.3% to $53.6 million in the quarter, short of the Zacks Consensus Estimate of $55 million. Quarter in Detail During the reported quarter, Testim sales in the US grew 17.9% to $47.4 million, mainly due to price increases and higher demand. Prescriptions increased 7.9% from the year-ago period. However, Testim faces significant competition in the form of Abbott’s (ABT) AndroGel. We note that Testim’s share of the US testosterone gel market declined in September. According to IMS Health, Testim exited the month of Sep 2010 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/24/auxl-auxilium-pharmaceuticals-reports-narrower-loss/58650/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Posts Narrower Third Quarter 2010 Loss</title>
		<link>http://www.stockbloghub.com/2010/11/17/slxp-salix-pharmaceuticals-posts-narrower-third-quarter-2010-loss/59433</link>
		<comments>http://www.stockbloghub.com/2010/11/17/slxp-salix-pharmaceuticals-posts-narrower-third-quarter-2010-loss/59433#comments</comments>
		<pubDate>Thu, 18 Nov 2010 05:19:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59433</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) posted a loss of 5 cents per share in the third quarter of 2010, narrower than the Zacks Consensus Estimate of a loss of 15 cents and the guidance provided by the company (loss of 13 cents). Salix had reported a loss of 15 cents in the year-ago quarter. Higher revenues helped the company post a narrower loss in the reported quarter. Third quarter revenues increased 22.8% to $80.6 million, mainly due to strong Xifaxan sales. Revenues were well above the company’s guidance of $73 million and the Zacks Consensus Estimate of $76 million. Quarter in Detail Salix’ third quarter performance was driven by its key product Xifaxan, which posted sales of $65.2 million, up 53%. Prescriptions grew 65% during the third quarter. Salix reported that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/17/slxp-salix-pharmaceuticals-posts-narrower-third-quarter-2010-loss/59433/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Company &#8211; Earnings Estimates Jump</title>
		<link>http://www.stockbloghub.com/2010/05/20/prgo-perrigo-company-earnings-estimates-jump/37760</link>
		<comments>http://www.stockbloghub.com/2010/05/20/prgo-perrigo-company-earnings-estimates-jump/37760#comments</comments>
		<pubDate>Thu, 20 May 2010 20:43:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37760</guid>
		<description><![CDATA[Perrigo Company (PRGO) recently hit a new multi-year high at $64.66 after reporting a solid Q3 earnings surprise of 21% in late April. Estimates are on the upswing and shares are trading in line with their industry peers. Company Description Perrigo Company, through its subsidiaries, develops, manufactures and sells over-the-counter, prescription pharmaceuticals, nutrition products and medical diagnostic products worldwide. The company was founded in 1887 and has a market cap of $5.23 billion. Even though shares of PRGO traded lower in 2008 and 2009 in the weak market, the company&#8217;s business barely blinked an eye, showing strong annual sales growth in a very challenging environment. That momentum has carried over to the recovery, on display with much better than expected Q3 results from April 29. Third-Quarter Results Revenue for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/20/prgo-perrigo-company-earnings-estimates-jump/37760/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Exceeds Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/05/17/slxp-salix-pharmaceuticals-exceeds-consensus-estimates/37432</link>
		<comments>http://www.stockbloghub.com/2010/05/17/slxp-salix-pharmaceuticals-exceeds-consensus-estimates/37432#comments</comments>
		<pubDate>Mon, 17 May 2010 22:26:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37432</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 45 cents per share in the first quarter of 2010, 6 cents better than the Zacks Consensus Estimate. The company had guided towards a net loss of 50 cents. Salix reported a net loss of 29 cents in the year-ago period. Net loss increased from the year-ago period mainly due to an increase in costs and a slight decline in revenues. First quarter revenues declined slightly (1.6%) to $44.1 million, mainly due to decreased unit sales of MoviPrep, OsmoPrep, Apriso and Pepcid. This was partially offset by increased unit sales of Xifaxan and price increases. Xifaxan sales increased 23.9% to $29.9 million with prescription demand growing 15% during the quarter. The bowel cleansing franchise, consisting of MoviPrep and OsmoPrep generated revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/17/slxp-salix-pharmaceuticals-exceeds-consensus-estimates/37432/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Auxilium Pharmaceuticals Reports Quarterly Loss That Narrows</title>
		<link>http://www.stockbloghub.com/2010/05/06/auxl-auxilium-pharmaceuticals-reports-quarterly-loss-that-narrows/36473</link>
		<comments>http://www.stockbloghub.com/2010/05/06/auxl-auxilium-pharmaceuticals-reports-quarterly-loss-that-narrows/36473#comments</comments>
		<pubDate>Thu, 06 May 2010 23:22:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AET]]></category>
		<category><![CDATA[Aetna Inc.]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[Health Net Inc.]]></category>
		<category><![CDATA[HNT]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36473</guid>
		<description><![CDATA[Strong Testim sales helped Auxilium Pharmaceuticals, Inc. (AUXL) report a narrower-than-expected net loss of 18 cents per share in the first quarter of 2010, 13 cents below the Zacks Consensus Estimate and year-ago net loss of 31 cents. Net revenues increased 31.1% to $45.5 million in the first quarter. During the reported quarter, Testim sales in the US grew 35% to $43.9 million, with prescriptions growing 14.8% from the year-ago period. According to IMS Health, Testim exited the month of Mar 2010 with a 22.4% share of the US testosterone gel market, up from the 21.6% share in the year-ago period. Worldwide Testim revenues were $44.2 million including product shipments outside the US. Auxilium expects Testim revenues in the range of $185 million to $195 million in 2010. Net revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/06/auxl-auxilium-pharmaceuticals-reports-quarterly-loss-that-narrows/36473/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HLF) Herbalife Incorporated &#8211; Earnings Estimates Up</title>
		<link>http://www.stockbloghub.com/2010/04/05/hlf-herbalife-incorporated-earnings-estimates-up/32722</link>
		<comments>http://www.stockbloghub.com/2010/04/05/hlf-herbalife-incorporated-earnings-estimates-up/32722#comments</comments>
		<pubDate>Mon, 05 Apr 2010 17:48:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Herbalife Limited]]></category>
		<category><![CDATA[HLF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32722</guid>
		<description><![CDATA[Herbalife, Inc. (HLF) recently hit a new 52-week high above $47 after shares jumped above a short-term level of resistance on strong Q4 results from late February and a bullish next-year estimate. Fourth-Quarter Results Shares of HLF rebounded from a key trend line after the company reported better than expected Q4 results on February 23. Sales were up 23% from last year to $630.9 million. Earnings also came in strong at 98 cents, 8% ahead of the Zacks Consensus Estimate. The company has surprised in each of the last four quarters by an average of 14% Herbalife results were driven by strength in its Asia Pacific segment, where sales were up 34.4% from the previous year. The company also tapped two new markets, breaking into both Vietnam and Paraguay. Estimates ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/05/hlf-herbalife-incorporated-earnings-estimates-up/32722/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Earns FDA Approval for Xifaxan</title>
		<link>http://www.stockbloghub.com/2010/03/29/slxp-salix-pharmaceuticals-earns-fda-approval-for-xifaxan/31997</link>
		<comments>http://www.stockbloghub.com/2010/03/29/slxp-salix-pharmaceuticals-earns-fda-approval-for-xifaxan/31997#comments</comments>
		<pubDate>Mon, 29 Mar 2010 17:49:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31997</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) received a huge boost recently with the US approval of Xifaxan 550 mg. The Food and Drug Administration (FDA) granted approval for the use of Xifaxan 550 mg in reducing the risk of the recurrence of overt hepatic encephalopathy (HE) in adult patients. The approval was in-line with expectations as the drug had received a favorable recommendation from the FDA’s Gastrointestinal Drugs Advisory Committee in Feb 2010. The additional indication for the drug is a major positive for Salix. Xifaxan is currently the primary growth driver at Salix following the entry of generic versions of Colazal in December 2007. Xifaxan (200 mg) is indicated for the treatment of patients 12 years of age and older with ‘travelers diarrhea’ caused by non-invasive strains of E coli. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/slxp-salix-pharmaceuticals-earns-fda-approval-for-xifaxan/31997/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Beats Forecasts but Outlook Disappoints</title>
		<link>http://www.stockbloghub.com/2010/03/10/slxp-salix-pharmaceuticals-beats-forecasts-but-outlook-disappoints/30236</link>
		<comments>http://www.stockbloghub.com/2010/03/10/slxp-salix-pharmaceuticals-beats-forecasts-but-outlook-disappoints/30236#comments</comments>
		<pubDate>Wed, 10 Mar 2010 20:17:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30236</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 13 cents per share in the fourth quarter, a penny better than the Zacks Consensus Estimate and company guidance of a net loss of 14 cents. Salix reported a net loss of 12 cents in the year-ago period. Higher product sales helped the company beat expectations despite an increase in costs. Full year net loss came in at 88 cents, a penny better than the Zacks Consensus Estimate and flat from the year-ago net loss. Revenues increased 30.3% to $232.9 million in 2009. Fourth quarter revenues increased 16% to $70.2 million, with Xifaxan sales increasing 4.6% to $24.9 million. The bowel cleansing franchise, consisting of MoviPrep, Visicol and OsmoPrep generated fourth quarter revenues of $30.4 million, up 54% from the year-ago ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/10/slxp-salix-pharmaceuticals-beats-forecasts-but-outlook-disappoints/30236/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HLF) Herbalife &#8211; Return on Equity of 64.8% is Far Ahead of Industry Average</title>
		<link>http://www.stockbloghub.com/2010/03/10/hlf-herbalife-return-on-equity-of-64-8-is-far-ahead-of-industry-average/30232</link>
		<comments>http://www.stockbloghub.com/2010/03/10/hlf-herbalife-return-on-equity-of-64-8-is-far-ahead-of-industry-average/30232#comments</comments>
		<pubDate>Wed, 10 Mar 2010 20:07:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Herbalife Limited]]></category>
		<category><![CDATA[HLF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30232</guid>
		<description><![CDATA[Herbalife (HLF) is expected to grow its earnings per share at 13.5% for the next five years. This Zacks Rank #2 stock also pays a decent dividend. Company Description Herbalife Ltd. is a global network marketing company that sells weight-management, nutrition and personal care products. Its products are sold in 72 countries through a network of approximately 1.9 million independent distributors. Fourth-Quarter Results Net sales increased 23.0% to $630.9 million. The company reported earnings per share of $0.91, topping the Zacks Consensus Estimate by $0.07. The company also provided its guidance for the first quarter and fiscal year 2010. For the first quarter, Herbalife expects EPS of $0.77-$0.80 and net sales growth of 12.5% to 13.5%. For fiscal 2010, the company now expects to earn between $3.58 and $3.70 per ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/10/hlf-herbalife-return-on-equity-of-64-8-is-far-ahead-of-industry-average/30232/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Focuses on Label Expansion</title>
		<link>http://www.stockbloghub.com/2010/03/08/slxp-salix-pharmaceuticals-focuses-on-label-expansion/29955</link>
		<comments>http://www.stockbloghub.com/2010/03/08/slxp-salix-pharmaceuticals-focuses-on-label-expansion/29955#comments</comments>
		<pubDate>Mon, 08 Mar 2010 15:52:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29955</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) is slated to report fourth quarter as well as fiscal 2009 results on March 9. The current Zacks Consensus Estimate for the fourth quarter of 2009 is a loss of 14 cents. For the full year, the Zacks Consensus Estimate stands at a loss of 89 cents. Salix suffered a major setback in Dec 2007 when its lead product, Colazal, started facing generics from several companies including Mylan (MYL). The genericization of Colazal adversely impacted the company’s top-and bottom-line. Since then, Salix has been working on reviving growth and is now focusing on gaining additional indications for its current growth driver, Xifaxan (rifaximin). More than earnings, we believe that investor focus will remain on the company’s success in gaining approval for additional indications of Xifaxan. Salix ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/08/slxp-salix-pharmaceuticals-focuses-on-label-expansion/29955/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NTY) NBTY Incorporated &#8211; Reports Record First Quarter Results</title>
		<link>http://www.stockbloghub.com/2010/03/03/nty-nbty-incorporated-reports-record-first-quarter-results/29520</link>
		<comments>http://www.stockbloghub.com/2010/03/03/nty-nbty-incorporated-reports-record-first-quarter-results/29520#comments</comments>
		<pubDate>Wed, 03 Mar 2010 23:04:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[NBTY Inc.]]></category>
		<category><![CDATA[NTY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29520</guid>
		<description><![CDATA[NBTY Inc. (NTY) recently surprised on estimates for the fourth quarter in a row as sales hit a first quarter record. NBTY has a forward P/E of just 11.9. Company Description NBTY manufactures and distributes nutritional supplements in the United States and around the globe. The company offers 25,000 products under the name brands Vitamin World, Puritan&#8217;s Pride, Holland &#38; Barrett, Rexall, Sundown, Worldwide Sport Nutrition and GNC (UK), among others. NBTY operates retail stores, a web site and a wholesale business. Sales Jumped 18% in January On Feb 9, the company released preliminary January sales figures which showed the momentum from 2009 continued unabated as sales climbed in every category. Wholesale/US Nutrition jumped the most, with 22% sales growth to $132 million from $109 million in January 2009. European ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/nty-nbty-incorporated-reports-record-first-quarter-results/29520/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Gets Good News From FDA</title>
		<link>http://www.stockbloghub.com/2010/03/01/slxp-salix-pharmaceuticals-gets-good-news-from-fda/29391</link>
		<comments>http://www.stockbloghub.com/2010/03/01/slxp-salix-pharmaceuticals-gets-good-news-from-fda/29391#comments</comments>
		<pubDate>Mon, 01 Mar 2010 23:34:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29391</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) received good news recently when the Food and Drug Administration&#8217;s (FDA) Gastrointestinal Drugs Advisory Committee recommended the approval of Xifaxan (500 mg) for the maintenance of remission of hepatic encephalopathy (HE). Xifaxan is currently the primary growth driver at Salix following the entry of generic versions of Colazal in December 2007. Xifaxan (200 mg) is indicated for the treatment of patients 12 years of age and older with traveler&#8217;s diarrhea caused by non-invasive strains of E coli. Approval for the HE indication would be a major boost for the company. The Committee voted 14 &#8211; 4 in favor of approval. While the FDA is not required to follow the Committee&#8217;s recommendation, it usually does so. A response from the FDA should be out by March 24, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/01/slxp-salix-pharmaceuticals-gets-good-news-from-fda/29391/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Auxilium Pharmaceuticals&#8217; Xiaflex Awarded FDA Approval</title>
		<link>http://www.stockbloghub.com/2010/02/03/auxl-auxilium-pharmaceuticals-xiaflex-awarded-fda-approval/26912</link>
		<comments>http://www.stockbloghub.com/2010/02/03/auxl-auxilium-pharmaceuticals-xiaflex-awarded-fda-approval/26912#comments</comments>
		<pubDate>Wed, 03 Feb 2010 20:19:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26912</guid>
		<description><![CDATA[Auxilium Pharmaceuticals, Inc. (AUXL) recently received a major boost when the U.S. Food and Drug Administration (FDA) granted approval to Xiaflex for the treatment of adult Dupuytren&#8217;s contracture patients with a palpable cord. The approval comes several months after an FDA advisory panel voted unanimously in favor of approving the product. Shares were up 9.5% in after-market trading. Dupuytren’s contracture is a condition that affects the connective tissue in the palm known as palmar fascia. The company estimates that approximately 240,000 Dupuytren’s candidates could exist in the U.S. and the EU. This represents significant commercial opportunity for Auxilium and the company could capture a significant share of the market as Xiaflex is the first and only FDA-approved non-surgical treatment for Dupuytren&#8217;s contracture. The FDA is requiring the company to make ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/03/auxl-auxilium-pharmaceuticals-xiaflex-awarded-fda-approval/26912/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Auxilium Pharmaceuticals and Pfizer Announces EU Review Process</title>
		<link>http://www.stockbloghub.com/2010/01/25/auxl-auxilium-pharmaceuticals-and-pfizer-announces-eu-review-process/25897</link>
		<comments>http://www.stockbloghub.com/2010/01/25/auxl-auxilium-pharmaceuticals-and-pfizer-announces-eu-review-process/25897#comments</comments>
		<pubDate>Mon, 25 Jan 2010 20:28:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25897</guid>
		<description><![CDATA[Auxilium Pharmaceuticals, Inc. (AUXL) and Pfizer Inc. (PFE) recently announced that the review process of their Marketing Authorization Application (MAA) for Xiaflex has commenced in the European Union. Pfizer was informed by the European Medicines Agency (EMEA) that the Xiaflex MAA has completed the validation phase successfully resulting in the commencement of the review process on Jan 21, 2010. Auxilium is now eligible to receive a $15 million milestone payment from Pfizer based on the commencement of the review process. The development, commercialization and supply agreement with Pfizer for Xiaflex covers Europe and certain Eurasian countries. Going forward, Auxilium can earn an additional $135 million in regulatory milestones and $260 million in sales milestones, along with a tiered double-digit royalty on sales at Pfizer. Pfizer and Auxilium are currently seeking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/25/auxl-auxilium-pharmaceuticals-and-pfizer-announces-eu-review-process/25897/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NTY) NBTY Incorporated &#8211; Consensus Earnings Estimates Jump</title>
		<link>http://www.stockbloghub.com/2010/01/15/nty-nbty-incorporated-consensus-earnings-estimates-jump/25060</link>
		<comments>http://www.stockbloghub.com/2010/01/15/nty-nbty-incorporated-consensus-earnings-estimates-jump/25060#comments</comments>
		<pubDate>Sat, 16 Jan 2010 00:38:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[NBTY Inc.]]></category>
		<category><![CDATA[NTY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25060</guid>
		<description><![CDATA[NBTY Inc. (NTY) recently announced preliminary fiscal first-quarter results which showed sales jumped 14%. The company has a PEG ratio of just 0.90 and is trading at 12.6x forward earnings. Company Description NBTY manufactures and distributes nutritional supplements in the United States and around the globe. The company offers 22,000 products under the name brands Vitamin World, Puritan&#8217;s Pride, Holland &#38; Barrett, Rexall, Sundown, Worldwide Sport Nutrition and GNC (UK), among others. NBTY operates retail stores, a web site and a wholesale business. NBTY Saw First Quarter Sales Rise 14% On Jan 12, NBTY announced preliminary net sales for both December and the fiscal first quarter. For December, net sales climbed 12% to $269 million from $241 million in the year ago period. The largest segment, Wholesale/US Nutrition, saw the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/15/nty-nbty-incorporated-consensus-earnings-estimates-jump/25060/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HLF) Herbalife Limited &#8211; Return on Equity of 65% Beats Industry Average of 15%</title>
		<link>http://www.stockbloghub.com/2010/01/15/hlf-herbalife-limited-return-on-equity-of-65-beats-industry-average-of-15/25066</link>
		<comments>http://www.stockbloghub.com/2010/01/15/hlf-herbalife-limited-return-on-equity-of-65-beats-industry-average-of-15/25066#comments</comments>
		<pubDate>Sat, 16 Jan 2010 00:35:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Herbalife Limited]]></category>
		<category><![CDATA[HLF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25066</guid>
		<description><![CDATA[Herbalife Ltd. (HLF) has more than doubled the market&#8217;s return over the past year. Analysts polled by Zacks boosted forecasts on Herbalife&#8217;s recent reaffirmation of 2009 and 2010 earnings outlook. Company Description Herbalife Ltd. is a global network marketing company that sells weight-management, nutrition and personal care products. Its products are sold in 72 countries through a network of approximately 1.9 million independent distributors. Bullish Forecasts and a Surging Share Price Herbalife recently reaffirmed its earnings guidance for the 2009 and 2010 years. The company sees earnings ranging between $3.19 &#8211; $3.22 per share for 2009 and between $3.50 &#8211; $3.65 for 2010. Analysts polled by Zacks hiked estimates in response. The 2009 Zacks Consensus Estimate of $3.20 per share was increased from $3.03 over the past 3 months. For ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/15/hlf-herbalife-limited-return-on-equity-of-65-beats-industry-average-of-15/25066/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals to File for IBS Indication</title>
		<link>http://www.stockbloghub.com/2009/12/16/slxp-salix-pharmaceuticals-to-file-for-ibs-indication/23023</link>
		<comments>http://www.stockbloghub.com/2009/12/16/slxp-salix-pharmaceuticals-to-file-for-ibs-indication/23023#comments</comments>
		<pubDate>Wed, 16 Dec 2009 22:54:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hawaiian Electric Industries Inc]]></category>
		<category><![CDATA[HE]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23023</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) recently held a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) related to the company’s new drug application (NDA) for rifaximin for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS). The meeting was conducted to discuss the completion of the company’s non-C IBS development program, the results of two phase III studies (TARGET 1 and TARGET 2), and to reach agreement on the content and format of the company’s NDA for the indication. TARGET 1 and TARGET 2 were conducted to evaluate the efficacy and safety of rifaximin 550 mg. Results showed that patients treated with rifaximin achieved a statistically significant improvement in the primary endpoint compared to placebo treated patients. Rifaximin also achieved statistical significance in the key secondary endpoint ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/slxp-salix-pharmaceuticals-to-file-for-ibs-indication/23023/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Company &#8211; Revenues Spike Year-Over-Year</title>
		<link>http://www.stockbloghub.com/2009/12/10/prgo-perrigo-company-revenues-spike-year-over-year/22452</link>
		<comments>http://www.stockbloghub.com/2009/12/10/prgo-perrigo-company-revenues-spike-year-over-year/22452#comments</comments>
		<pubDate>Thu, 10 Dec 2009 21:59:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22452</guid>
		<description><![CDATA[Perrigo Co. (PRGO) analysts are steadily increasing estimates for the drug company, fueled by the latest earnings surprise. Company Description Perrigo Co. makes OTC and generic prescription drugs, nutritional products, pharmaceutical ingredients, and other consumer products. Currently it is the biggest manufacturer of store brand OTC pharmaceuticals. Operations are in North America and Europe. Revenues Spike In a Nov 2 report, the company announced first-quarter results that included revenue of $528 million. This was up 16% year-over-year. Net income came in at $61 million, or 66 cents per share. The Zacks Consensus Estimate was 49 cents, making this a 35% beat and the third consecutive earnings surprise. Estimates Climbing Following the announcement, full-year estimates jumped to $2.42, from $2.10. The Zacks Consensus Estimate for next year is now $2.62, up ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/10/prgo-perrigo-company-revenues-spike-year-over-year/22452/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HLF) Herbalife Ltd. &#8211; Analysts Polled Remain Bullish on Earnings</title>
		<link>http://www.stockbloghub.com/2009/12/07/hlf-herbalife-ltd-analysts-polled-remain-bullish-on-earnings/22109</link>
		<comments>http://www.stockbloghub.com/2009/12/07/hlf-herbalife-ltd-analysts-polled-remain-bullish-on-earnings/22109#comments</comments>
		<pubDate>Mon, 07 Dec 2009 19:02:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Herbalife Limited]]></category>
		<category><![CDATA[HLF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22109</guid>
		<description><![CDATA[Herbalife Ltd. (HLF) continues to trade higher, closing in on a 52-week high and outpacing the market since the stock was last featured as a Momentum pick. During the past year, shares soared about 130% past the S&#38;P 500. Analysts polled by Zacks remain bullish on earnings, lifting full-year estimates 6% to $3.20 per share over the past 60 days. For 2010, the Zacks Consensus Estimate of $3.65 per share was upped from last month&#8217;s $3.60 and the 2 months-ago level of $3.39. Herbalife boasts strong fundamentals Incorporatedluding an attractive valuation with a forward P/E of 13. The company&#8217;s net profit margin 8% compares favorably to a negative industry average. Herbalife rewards shareholders with an industry-leading dividend yield of 2%. Alex Kolb is the Growth &#38; Income Stock Strategist for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/07/hlf-herbalife-ltd-analysts-polled-remain-bullish-on-earnings/22109/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NTY) NBTY Incorporated &#8211; Reports Record Fourth Quarter Results</title>
		<link>http://www.stockbloghub.com/2009/11/14/nty-nbty-incorporated-reports-record-fourth-quarter-results/20408</link>
		<comments>http://www.stockbloghub.com/2009/11/14/nty-nbty-incorporated-reports-record-fourth-quarter-results/20408#comments</comments>
		<pubDate>Sun, 15 Nov 2009 00:26:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[NBTY Inc.]]></category>
		<category><![CDATA[NTY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20408</guid>
		<description><![CDATA[NBTY Inc. (NTY) just posted record results for the fiscal fourth quarter as sales jumped 12%. The company is not only a value stock but analysts expect earnings to grow at 13.75% over the next 5 years. NBTY has a PEG ratio of just 0.90. Company Description NBTY manufactures and distributes nutritional supplements in the United States and around the globe. The company offers 22,000 products under the name brands Vitamin World, Puritan&#8217;s Pride, Holland &#38; Barrett, Rexall, Sundown, Worldwide Sport Nutrition and GNC (UK), among others. NBTY Reports Record Fourth Quarter Results On Nov 9, NBTY reported fiscal fourth quarter results which easily beat on the Zacks Consensus Estimate by 12.05%. Earnings per share were 93 cents compared to the Zacks Consensus of 83 cents. EPS was 28 cents ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/nty-nbty-incorporated-reports-record-fourth-quarter-results/20408/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HLF) Herbalife Limited &#8211; Earnings Estimates Advance</title>
		<link>http://www.stockbloghub.com/2009/11/14/hlf-herbalife-limited-earnings-estimates-advance/20479</link>
		<comments>http://www.stockbloghub.com/2009/11/14/hlf-herbalife-limited-earnings-estimates-advance/20479#comments</comments>
		<pubDate>Sat, 14 Nov 2009 23:48:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Herbalife Limited]]></category>
		<category><![CDATA[HLF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20479</guid>
		<description><![CDATA[Herbalife Ltd. (HLF) recently spiked higher after reporting better than expected third-quarter results. Company Description Herbalife Ltd. is a network marketing company that sells weight management and nutritional supplements worldwide. The company was founded in 1980 and has a market cap of $2.54 billion. Shares of HLF recently spiked higher on the company&#8217;s better than expected third-quarter results after rebounding from a longer-term trend line that has been supporting prices for the last 8 months. Third-Quarter Results Sales were mostly flat from last year, but earnings came in better than expected at 85 cents per share, 16 cents ahead of the Zacks Consensus Estimate. Herbalife has beat in each of the last four quarters by an average of 8 cents, or 12%. The company also noted that it reduced its ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/hlf-herbalife-limited-earnings-estimates-advance/20479/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Beats Expectation on Xifaxan&#8217;s Strength</title>
		<link>http://www.stockbloghub.com/2009/11/12/slxp-salix-pharmaceuticals-beats-expectation-on-xifaxans-strength/20386</link>
		<comments>http://www.stockbloghub.com/2009/11/12/slxp-salix-pharmaceuticals-beats-expectation-on-xifaxans-strength/20386#comments</comments>
		<pubDate>Thu, 12 Nov 2009 16:19:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20386</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 15 cents per share in the third quarter, which was significantly better than the Zacks Consensus Estimate of a net loss of 29 cents. The company reported a net loss of 11 cents in the year-ago period. Although revenue increased from the year-ago period, higher operating expenses led to the year-over-year increase in net loss. Total product revenue was $65.7 million, up 53%. Xifaxan continued to perform well with revenue almost doubling to $42.7 million. We believe wholesaler stocking, price increases and prescription growth were responsible for the significant increase in Xifaxan revenue. Based on the current run rate, we expect Xifaxan revenue to exceed $115 million in 2009. The bowel cleansing franchise, consisting of MoviPrep, Visicol and OsmoPrep generated revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/12/slxp-salix-pharmaceuticals-beats-expectation-on-xifaxans-strength/20386/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Auxilium Pharma Awaiting FDA Decision</title>
		<link>http://www.stockbloghub.com/2009/10/14/auxl-auxilium-pharma-awaiting-fda-decision/17578</link>
		<comments>http://www.stockbloghub.com/2009/10/14/auxl-auxilium-pharma-awaiting-fda-decision/17578#comments</comments>
		<pubDate>Wed, 14 Oct 2009 17:08:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17578</guid>
		<description><![CDATA[Auxilium Pharma (AUXL) is currently awaiting a decision from the U.S. Food and Drug Administration (FDA) on its key pipeline candidate, Xiaflex, which is under FDA review for the treatment of Dupuytren’s Contracture. In September, Auxilium received a major boost in the form of a favorable recommendation from the FDA’s Arthritis Advisory Committee for Xiaflex for the treatment of Dupuytren’s Contracture. Dupuytren’s Contracture is a condition that affects the connective tissue in the palm known as palmar fascia. The company estimates that approximately 240,000 Dupuytren’s candidates could exist in the U.S. and the EU. This represents significant commercial opportunity for Auxilium. Xiaflex is also being studied for the treatment of Peyronie’s disease and frozen shoulder syndrome. According to the company, there are at least 450,000 potential patients annually in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/14/auxl-auxilium-pharma-awaiting-fda-decision/17578/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Company &#8211; PEG Ratio of Just 0.94 &#8211; Growth Expected to Continue in Fiscal 2010</title>
		<link>http://www.stockbloghub.com/2009/10/13/prgo-perrigo-company-peg-ratio-of-just-0-94-growth-expected-to-continue-in-fiscal-2010/17502</link>
		<comments>http://www.stockbloghub.com/2009/10/13/prgo-perrigo-company-peg-ratio-of-just-0-94-growth-expected-to-continue-in-fiscal-2010/17502#comments</comments>
		<pubDate>Tue, 13 Oct 2009 19:40:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17502</guid>
		<description><![CDATA[Perrigo Company (PRGO) has surprised on estimates the last two quarters as it reported record sales for fiscal 2009. PRGO has a PEG ratio of just 0.94. Company Description Perrigo manufactures over-the-counter and prescription pharmaceuticals, nutritional products and other consumer products. It also provides over-the-counter (OTC) products for various stores under those store brand names. For instance, it manufactures an acetaminophen product similar to the Tylenol brand. Record Sales in 2009 On Aug 18, Perrigo reported fiscal fourth-quarter and full year 2009 results and saw record sales and earnings for the year. It was the first year the company reported $2 billion in sales, which was a 16% rise from 2008. It was also the second year in a row of record sales. The increase was driven by new product ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/13/prgo-perrigo-company-peg-ratio-of-just-0-94-growth-expected-to-continue-in-fiscal-2010/17502/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Gets Marketing Approval</title>
		<link>http://www.stockbloghub.com/2009/09/09/slxp-salix-pharmaceuticals-gets-marketing-approval/14785</link>
		<comments>http://www.stockbloghub.com/2009/09/09/slxp-salix-pharmaceuticals-gets-marketing-approval/14785#comments</comments>
		<pubDate>Thu, 10 Sep 2009 02:32:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Salix Pharmaceuticals Ltd.]]></category>
		<category><![CDATA[Santarus Inc]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNTS]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14785</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) received positive news yesterday when the U.S. Food and Drug Administration (FDA) granted marketing approval for Metozolv ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. Metozolv ODT received approval for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy. Metozolv ODT’s orally disintegrating formulation should make the product more convenient to use especially in the case of patients who have difficulty swallowing or do not have water available when treatment is needed. According to the company, gastroparesis is estimated to affect up to five million people in the United States, with females being at a higher ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/slxp-salix-pharmaceuticals-gets-marketing-approval/14785/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals&#8217; Drug Gets Priority Status</title>
		<link>http://www.stockbloghub.com/2009/08/26/slxp-salix-pharmaceuticals-drug-gets-priority-status/13421</link>
		<comments>http://www.stockbloghub.com/2009/08/26/slxp-salix-pharmaceuticals-drug-gets-priority-status/13421#comments</comments>
		<pubDate>Wed, 26 Aug 2009 15:31:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Ltd.]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13421</guid>
		<description><![CDATA[Salix Pharmaceuticals Ltd. (SLXP) yesterday announced that the U.S. Food and Drug Administration (FDA) has granted priority review status to its new drug application (NDA) for  rifaximin 550 mg. Salix is seeking approval for the use of rifaximin for the maintenance of remission of hepatic encephalopathy (HE). Priority review status is granted to drugs, which offer major advances in treatment or provide a treatment where no adequate therapy is available. Rifaximin has also been granted Orphan Drug designation in the U.S. for the HE indication. While the FDA has issued an action date of Dec 24, we believe the FDA decision will be pushed back by a few months as the candidate is expected to come up for review by an FDA advisory committee in late February 2010. According to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/26/slxp-salix-pharmaceuticals-drug-gets-priority-status/13421/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Trading FDA Decisions with Calendar Spreads</title>
		<link>http://www.stockbloghub.com/2009/07/16/auxl-trading-fda-decisions-with-calendar-spreads/10058</link>
		<comments>http://www.stockbloghub.com/2009/07/16/auxl-trading-fda-decisions-with-calendar-spreads/10058#comments</comments>
		<pubDate>Thu, 16 Jul 2009 23:06:51 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=10058</guid>
		<description><![CDATA[Joe Kunkle, The Investment U Research Team FDA approvals/rejections of drugs can make or break a Biotech company. These decisions can be incredibly volatile and profitable if you’re positioned correctly. There have been instances where shares lose more than three-fourths of its value and other cases where a company rises 900% or more in a single day (like Vanda Pharmaceuticals recently). In most instances, it’s pretty clear when the FDA will make a decision on a key drug, often named the PDUFA data. Also, companies generally make available dates that it will present top line data from drugs, before it submits it to the FDA for approval of an NDA (New Drug Application). The information on FDA decisions and announcement dates are out there. And many talented investors make a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/16/auxl-trading-fda-decisions-with-calendar-spreads/10058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Company &#8211; ROE of 17% &#8211; more than the double the industry average of 8%</title>
		<link>http://www.stockbloghub.com/2009/01/14/prgo-perrigo-company-roe-of-17-more-than-the-double-the-industry-average-of-8/2106</link>
		<comments>http://www.stockbloghub.com/2009/01/14/prgo-perrigo-company-roe-of-17-more-than-the-double-the-industry-average-of-8/2106#comments</comments>
		<pubDate>Thu, 15 Jan 2009 01:47:15 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2106</guid>
		<description><![CDATA[Perrigo Co. (PRGO) has a return on equity (ROE) of 17%, more than the double the industry’s average of 8%. The company’s earnings per share are expected to grow by 21% over the next 3 – 5 years, while the industry average expectation stands at 15%. Company Description Perrigo is the nation&#8217;s largest manufacturer of store brand over-the-counter (non-prescription) pharmaceutical products and it manufactures store brand nutritional products. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company&#8217;s products include analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and vitamins, nutritional supplements and nutritional drinks. Recent Events The company recently announced that it received final approval from the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/14/prgo-perrigo-company-roe-of-17-more-than-the-double-the-industry-average-of-8/2106/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PBH) Prestige Brands &#8211; Prestige Brands distributes over-the-counter healthcare, personal care and household products</title>
		<link>http://www.stockbloghub.com/2008/12/10/pbh-prestige-brands-holdings-prestige-brands-distributes-over-the-counter-healthcare-personal-care-and-household-products/1658</link>
		<comments>http://www.stockbloghub.com/2008/12/10/pbh-prestige-brands-holdings-prestige-brands-distributes-over-the-counter-healthcare-personal-care-and-household-products/1658#comments</comments>
		<pubDate>Wed, 10 Dec 2008 23:04:08 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PBH]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1658</guid>
		<description><![CDATA[Prestige Brands Holdings, Inc. (PBH) is weathering the economic storm with its strong brands such as Comet and Little Remedies. Net income for the second quarter grew 25% from a year ago. PBH is trading at 9.8x forward earnings. Company Description Prestige Brands distributes over-the-counter healthcare, personal care and household products throughout the world. For 75 years, the company has been marketing Spic and Span products and also distributes famous brands including Compound W wart treatment, Chloraseptic sore throat products, Cutex nail polish remover and Little Remedies pediatric over-the-counter healthcare products. Second Quarter Net Income Jumped 25% On Nov 6, Prestige Brands reported second-quarter 2009 earnings that matched Wall Street estimates. Net income rose 25% to $8.5 million, or 17 cents, from $6.8 million, or 14 cents per share in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/12/10/pbh-prestige-brands-holdings-prestige-brands-distributes-over-the-counter-healthcare-personal-care-and-household-products/1658/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo Company &#8211; largest manufacturer of store brand over-the-counter pharmaceutical products</title>
		<link>http://www.stockbloghub.com/2008/10/25/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products-4/1073</link>
		<comments>http://www.stockbloghub.com/2008/10/25/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products-4/1073#comments</comments>
		<pubDate>Sat, 25 Oct 2008 14:41:28 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/0011073/2008/10/25/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products-4</guid>
		<description><![CDATA[Perrigo Company (PRGO) has acquired 2 more laboratories this quarter in a focused effort on growth in existing markets. The company is also coming off of a record quarterly earnings report.Company Description Perrigo is the nations largest manufacturer of store brand over-the-counter pharmaceutical products and also manufactures store brand nutritional products. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company&#8217;s products include analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and vitamins, nutritional supplements and nutritional drinks. Acquired Mexican Manufacturer On Oct 6 Perrigo announced that it acquired Laboratorios Diba S.A. in an all-cash transaction for $25 million. The manufacturer is expected to add $15 million in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/25/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products-4/1073/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo Company &#8211; largest manufacturer of store brand over-the-counter pharmaceutical products</title>
		<link>http://www.stockbloghub.com/2008/10/24/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products-3/1043</link>
		<comments>http://www.stockbloghub.com/2008/10/24/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products-3/1043#comments</comments>
		<pubDate>Fri, 24 Oct 2008 12:42:21 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/0011043/2008/10/24/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products-3</guid>
		<description><![CDATA[Perrigo Company (PRGO) has acquired 2 more laboratories this quarter in a focused effort on growth in existing markets. The company is also coming off of a record quarterly earnings report.Company Description Perrigo is the nations largest manufacturer of store brand over-the-counter pharmaceutical products and also manufactures store brand nutritional products. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company&#8217;s products include analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and vitamins, nutritional supplements and nutritional drinks. Acquired Mexican Manufacturer On Oct 6 Perrigo announced that it acquired Laboratorios Diba S.A. in an all-cash transaction for $25 million. The manufacturer is expected to add $15 million in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/24/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products-3/1043/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo Company &#8211; largest manufacturer of store brand over-the-counter pharmaceutical products</title>
		<link>http://www.stockbloghub.com/2008/10/17/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products-2/1000</link>
		<comments>http://www.stockbloghub.com/2008/10/17/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products-2/1000#comments</comments>
		<pubDate>Fri, 17 Oct 2008 16:00:27 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/0011000/2008/10/17/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products-2</guid>
		<description><![CDATA[Perrigo Company (PRGO) has acquired 2 more laboratories this quarter in a focused effort on growth in existing markets. The company is also coming off of a record quarterly earnings report.Company Description Perrigo is the nations largest manufacturer of store brand over-the-counter pharmaceutical products and also manufactures store brand nutritional products. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company&#8217;s products include analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and vitamins, nutritional supplements and nutritional drinks. Acquired Mexican Manufacturer On Oct 6 Perrigo announced that it acquired Laboratorios Diba S.A. in an all-cash transaction for $25 million. The manufacturer is expected to add $15 million in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/17/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products-2/1000/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo Company &#8211; largest manufacturer of store brand over-the-counter pharmaceutical products</title>
		<link>http://www.stockbloghub.com/2008/10/16/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products/969</link>
		<comments>http://www.stockbloghub.com/2008/10/16/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products/969#comments</comments>
		<pubDate>Fri, 17 Oct 2008 03:00:23 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001969/2008/10/16/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products</guid>
		<description><![CDATA[Perrigo Company (PRGO) has acquired 2 more laboratories this quarter in a focused effort on growth in existing markets. The company is also coming off of a record quarterly earnings report.Company Description Perrigo is the nations largest manufacturer of store brand over-the-counter pharmaceutical products and also manufactures store brand nutritional products. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company&#8217;s products include analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and vitamins, nutritional supplements and nutritional drinks. Acquired Mexican Manufacturer On Oct 6 Perrigo announced that it acquired Laboratorios Diba S.A. in an all-cash transaction for $25 million. The manufacturer is expected to add $15 million in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/16/prgo-perrigo-company-largest-manufacturer-of-store-brand-over-the-counter-pharmaceutical-products/969/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo &#8211; profit increased by 46% from demand for its consumer health care products</title>
		<link>http://www.stockbloghub.com/2008/10/15/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-5/928</link>
		<comments>http://www.stockbloghub.com/2008/10/15/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-5/928#comments</comments>
		<pubDate>Wed, 15 Oct 2008 12:00:09 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001928/2008/10/15/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-5</guid>
		<description><![CDATA[Perrigo Co. (PRGO) has been performing well in a down market, and analysts have been boosting forecasts. Fiscal full-year earnings estimates are up 2% in just the past week. The company announced record fiscal fourth-quarter results in mid-August.Company Description Perrigo is the nation&#8217;s largest manufacturer of store brand over-the-counter (non-prescription) pharmaceutical products and it manufactures store brand nutritional products. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company&#8217;s products include analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and vitamins, nutritional supplements and nutritional drinks. Recent Events The company recently announced that it was dismissed from a patent infringement lawsuit. Earlier Johnson &#38; Johnson’s (JNJ) McNeil unit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/15/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-5/928/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo &#8211; profit increased by 46% from demand for its consumer health care products</title>
		<link>http://www.stockbloghub.com/2008/10/09/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-4/882</link>
		<comments>http://www.stockbloghub.com/2008/10/09/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-4/882#comments</comments>
		<pubDate>Thu, 09 Oct 2008 13:01:10 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001882/2008/10/09/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-4</guid>
		<description><![CDATA[Perrigo Co. (PRGO) has been performing well in a down market, and analysts have been boosting forecasts. Fiscal full-year earnings estimates are up 2% in just the past week. The company announced record fiscal fourth-quarter results in mid-August.Company Description Perrigo is the nation&#8217;s largest manufacturer of store brand over-the-counter (non-prescription) pharmaceutical products and it manufactures store brand nutritional products. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company&#8217;s products include analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and vitamins, nutritional supplements and nutritional drinks. Recent Events The company recently announced that it was dismissed from a patent infringement lawsuit. Earlier Johnson &#38; Johnson’s (JNJ) McNeil unit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/09/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-4/882/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo &#8211; profit increased by 46% from demand for its consumer health care products</title>
		<link>http://www.stockbloghub.com/2008/10/07/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-3/822</link>
		<comments>http://www.stockbloghub.com/2008/10/07/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-3/822#comments</comments>
		<pubDate>Tue, 07 Oct 2008 13:22:02 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001822/2008/10/07/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-3</guid>
		<description><![CDATA[Perrigo Co. (PRGO) has been performing well in a down market, and analysts have been boosting forecasts. Fiscal full-year earnings estimates are up 2% in just the past week. The company announced record fiscal fourth-quarter results in mid-August.Company Description Perrigo is the nation&#8217;s largest manufacturer of store brand over-the-counter (non-prescription) pharmaceutical products and it manufactures store brand nutritional products. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company&#8217;s products include analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and vitamins, nutritional supplements and nutritional drinks. Recent Events The company recently announced that it was dismissed from a patent infringement lawsuit. Earlier Johnson &#38; Johnson’s (JNJ) McNeil unit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/07/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-3/822/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo &#8211; profit increased by 46% from demand for its consumer health care products</title>
		<link>http://www.stockbloghub.com/2008/10/02/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-2/777</link>
		<comments>http://www.stockbloghub.com/2008/10/02/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-2/777#comments</comments>
		<pubDate>Thu, 02 Oct 2008 16:20:21 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001777/2008/10/02/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-2</guid>
		<description><![CDATA[Perrigo Co. (PRGO) has been performing well in a down market, and analysts have been boosting forecasts. Fiscal full-year earnings estimates are up 2% in just the past week. The company announced record fiscal fourth-quarter results in mid-August.Company Description Perrigo is the nation&#8217;s largest manufacturer of store brand over-the-counter (non-prescription) pharmaceutical products and it manufactures store brand nutritional products. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company&#8217;s products include analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and vitamins, nutritional supplements and nutritional drinks. Recent Events The company recently announced that it was dismissed from a patent infringement lawsuit. Earlier Johnson &#38; Johnson’s (JNJ) McNeil unit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/02/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products-2/777/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo &#8211; profit increased by 46% from demand for its consumer health care products</title>
		<link>http://www.stockbloghub.com/2008/10/01/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products/744</link>
		<comments>http://www.stockbloghub.com/2008/10/01/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products/744#comments</comments>
		<pubDate>Thu, 02 Oct 2008 03:20:20 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001744/2008/10/01/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products</guid>
		<description><![CDATA[Perrigo Co. (PRGO) has been performing well in a down market, and analysts have been boosting forecasts. Fiscal full-year earnings estimates are up 2% in just the past week. The company announced record fiscal fourth-quarter results in mid-August.Company Description Perrigo is the nation&#8217;s largest manufacturer of store brand over-the-counter (non-prescription) pharmaceutical products and it manufactures store brand nutritional products. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company&#8217;s products include analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and vitamins, nutritional supplements and nutritional drinks. Recent Events The company recently announced that it was dismissed from a patent infringement lawsuit. Earlier Johnson &#38; Johnson’s (JNJ) McNeil unit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/01/prgo-perrigo-profit-increased-by-46-from-demand-for-its-consumer-health-care-products/744/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo  &#8211; return on equity (ROE) of 18%, which more than doubles the industry average of 7%</title>
		<link>http://www.stockbloghub.com/2008/09/23/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7-4/659</link>
		<comments>http://www.stockbloghub.com/2008/09/23/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7-4/659#comments</comments>
		<pubDate>Tue, 23 Sep 2008 11:20:46 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001659/2008/09/23/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7-4</guid>
		<description><![CDATA[Perrigo Co. (PRGO) is seeing higher forecasts from analysts. The company offers a return on equity (ROE) of 18%, which more than doubles the industry average of 7%. Earnings per share are expected to grow by 20% over the next 3 – 5 years, outpacing the industry average of 15%.Company Description Perrigo Company is a healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The company is the world&#8217;s largest manufacturer of OTC pharmaceutical products for the store brand market. PRGO’s primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Recent Events The company recently announced that it acquired the exclusive U.S. rights to sell and distribute Levocetirizine tablets, the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/09/23/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7-4/659/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo  &#8211; return on equity (ROE) of 18%, which more than doubles the industry average of 7%</title>
		<link>http://www.stockbloghub.com/2008/09/19/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7-3/620</link>
		<comments>http://www.stockbloghub.com/2008/09/19/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7-3/620#comments</comments>
		<pubDate>Fri, 19 Sep 2008 12:01:07 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001620/2008/09/19/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7-3</guid>
		<description><![CDATA[Perrigo Co. (PRGO) is seeing higher forecasts from analysts. The company offers a return on equity (ROE) of 18%, which more than doubles the industry average of 7%. Earnings per share are expected to grow by 20% over the next 3 – 5 years, outpacing the industry average of 15%.Company Description Perrigo Company is a healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The company is the world&#8217;s largest manufacturer of OTC pharmaceutical products for the store brand market. PRGO’s primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Recent Events The company recently announced that it acquired the exclusive U.S. rights to sell and distribute Levocetirizine tablets, the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/09/19/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7-3/620/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo  &#8211; return on equity (ROE) of 18%, which more than doubles the industry average of 7%</title>
		<link>http://www.stockbloghub.com/2008/09/17/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7-2/586</link>
		<comments>http://www.stockbloghub.com/2008/09/17/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7-2/586#comments</comments>
		<pubDate>Wed, 17 Sep 2008 12:21:13 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001586/2008/09/17/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7-2</guid>
		<description><![CDATA[Perrigo Co. (PRGO) is seeing higher forecasts from analysts. The company offers a return on equity (ROE) of 18%, which more than doubles the industry average of 7%. Earnings per share are expected to grow by 20% over the next 3 – 5 years, outpacing the industry average of 15%.Company Description Perrigo Company is a healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The company is the world&#8217;s largest manufacturer of OTC pharmaceutical products for the store brand market. PRGO’s primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Recent Events The company recently announced that it acquired the exclusive U.S. rights to sell and distribute Levocetirizine tablets, the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/09/17/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7-2/586/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) &#8211; Perrigo  &#8211; return on equity (ROE) of 18%, which more than doubles the industry average of 7%</title>
		<link>http://www.stockbloghub.com/2008/09/12/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7/554</link>
		<comments>http://www.stockbloghub.com/2008/09/12/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7/554#comments</comments>
		<pubDate>Sat, 13 Sep 2008 04:20:08 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[PRGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001554/2008/09/12/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7</guid>
		<description><![CDATA[Perrigo Co. (PRGO) is seeing higher forecasts from analysts. The company offers a return on equity (ROE) of 18%, which more than doubles the industry average of 7%. Earnings per share are expected to grow by 20% over the next 3 – 5 years, outpacing the industry average of 15%.Company Description Perrigo Company is a healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The company is the world&#8217;s largest manufacturer of OTC pharmaceutical products for the store brand market. PRGO’s primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Recent Events The company recently announced that it acquired the exclusive U.S. rights to sell and distribute Levocetirizine tablets, the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/09/12/prgo-perrigo-return-on-equity-roe-of-18-which-more-than-doubles-the-industry-average-of-7/554/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

